Megmilk Snow Brand - US12599639B2 Joint Function-Improving Composition Patent
Summary
USPTO granted patent US12599639B2 to MEGMILK SNOW BRAND CO., LTD. for a joint function-improving composition containing bacterial cells and/or cultures of Lactobacillus, Lactococcus, Streptococcus, or Bifidobacterium genera combined with a joint function-improving agent. The composition targets prevention or treatment of osteoarthritis and rheumatoid arthritis through chondrocyte growth promotion and suppression of inflammation, cartilage degradation, pain, and neuronal outgrowth factors. The patent covers food, drink, feed, and pharmaceutical applications.
What changed
USPTO granted patent US12599639B2 to Megmilk Snow Brand Co., Ltd. covering a joint function-improving composition containing bacterial cells and/or cultures from genera Lactobacillus, Lactococcus, Streptococcus, or Bifidobacterium combined with joint function-improving agents. The composition is designed for food, drink, feed, and pharmaceutical use targeting osteoarthritis and rheumatoid arthritis.
Patent grants establish intellectual property rights and do not create new compliance obligations on third parties. Affected parties in the therapeutic bacterial culture and joint health supplement markets should monitor this IP landscape as the patent grants exclusive rights to the composition and its applications in the United States.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Joint function-improving composition
Grant US12599639B2 Kind: B2 Apr 14, 2026
Assignee
MEGMILK SNOW BRAND CO., LTD.
Inventors
Ayatake Nakano, Takehiko Yasueda, Yasuyuki Seto
Abstract
An object is to provide a joint function-improving composition which is useful for prevention or treatment of various arthropathies such as osteoarthritis including knee osteoarthritis as a typical example and rheumatoid arthritis because the composition has an action of promoting growth of chondrocytes and an action of suppressing the production of an inflammation factor, a cartilage matrix degradation factor, a pain factor or a neuronal outgrowth factor by synoviocytes and to provide a joint function-improving product containing the composition such as a food or a drink, feed and a medicine. A joint function-improving composition containing bacterial cells and/or a culture of a bacterium belonging to genera Lactobacillus, Lactococcus, Streptococcus or Bifidobacterium and a joint function-improving agent, a joint function-improving food or drink, a joint function-improving nutritional composition, joint function-improving feed or a joint function-improving pharmaceutical agent which is characterized by containing the joint function-improving composition.
CPC Classifications
A61K 35/747 A61K 35/745 A61P 19/02 C12N 1/205 C12R 2001/46 C12R 2001/23
Filing Date
2022-01-07
Application No.
18271259
Claims
1
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.